Brokerages Set Indivior PLC (NASDAQ:INDV) PT at $22.00

Indivior PLC (NASDAQ:INDV) has received a consensus rating of “Moderate Buy” from the eight brokerages that are covering the stock, MarketBeat reports. Two research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company. The average 12 month target price among brokers that have updated their coverage on the stock in the last year is $32.1667.

INDV has been the topic of several analyst reports. HC Wainwright raised their price target on shares of Indivior from $28.00 to $35.00 and gave the company a “buy” rating in a research report on Thursday, October 30th. Jefferies Financial Group initiated coverage on shares of Indivior in a research report on Tuesday, July 22nd. They set a “buy” rating and a $20.00 price target on the stock. Zacks Research lowered shares of Indivior from a “strong-buy” rating to a “hold” rating in a research report on Friday, October 3rd. Weiss Ratings restated a “hold (c)” rating on shares of Indivior in a research report on Friday. Finally, Craig Hallum restated a “buy” rating and set a $41.00 price target on shares of Indivior in a research report on Friday.

Indivior Price Performance

Shares of Indivior stock opened at $31.20 on Thursday. The firm has a fifty day moving average price of $24.38 and a 200 day moving average price of $18.42. Indivior has a 1 year low of $7.62 and a 1 year high of $31.63. The stock has a market cap of $4.30 billion, a PE ratio of 50.32 and a beta of 0.70.

Indivior (NASDAQ:INDV) last released its quarterly earnings results on Thursday, October 30th. The company reported $0.72 EPS for the quarter, beating the consensus estimate of $0.38 by $0.34. The company had revenue of $314.00 million for the quarter, compared to analyst estimates of $257.66 million. Indivior had a net margin of 6.65% and a negative return on equity of 86.28%. Indivior has set its FY 2025 guidance at EPS. As a group, equities analysts expect that Indivior will post 1.22 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the stock. Landscape Capital Management L.L.C. raised its position in shares of Indivior by 78.1% during the 1st quarter. Landscape Capital Management L.L.C. now owns 140,137 shares of the company’s stock worth $1,336,000 after purchasing an additional 61,455 shares during the last quarter. Acadian Asset Management LLC acquired a new position in Indivior during the first quarter worth about $6,328,000. State of New Jersey Common Pension Fund D acquired a new position in Indivior during the second quarter worth about $262,000. Vanguard Group Inc. boosted its position in Indivior by 1.6% during the first quarter. Vanguard Group Inc. now owns 4,631,221 shares of the company’s stock worth $43,765,000 after acquiring an additional 71,539 shares during the last quarter. Finally, Jane Street Group LLC boosted its position in Indivior by 2,597.9% during the first quarter. Jane Street Group LLC now owns 995,013 shares of the company’s stock worth $9,327,000 after acquiring an additional 958,132 shares during the last quarter. Institutional investors and hedge funds own 60.33% of the company’s stock.

Indivior Company Profile

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.